
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes.
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes. This would solve some of the problems faced when using the e-PRO devices employed today:
Click






